Literature DB >> 26836326

Hepatitis A and B screening and vaccination rates among patients with chronic liver disease.

Jonathan C Ramirez1, Kimberly Ackerman1, Sasha C Strain1, Syed T Ahmed1, Mario J de Los Santos1, Dawn Sears1.   

Abstract

Vaccinations against hepatitis A virus (HAV) and hepatitis B virus (HBV) are recommended for patients with chronic liver disease (CLD), yet implementation of these recommendations is lacking. This study reviewed HAV and HBV antibody testing and vaccination status of patients with CLD. In 2008, we began using pre-printed liver order sets, which included vaccination options. We compared Scott & White liver clinic CLD patient records from 2005 (238) with patient records from 2008 (792). Screening rates for immunity and vaccination rates of those lacking immunity were calculated. In 2005, 66% of CLD patients were screened for HAV immunity. In 2008, 56% of CLD patients were screened. The HAV vaccination completion rate was 37% in 2005, while in 2008, the rate was 46%. In 2005, 66% of CLD patients were screened for HBV immunity; in 2008, 56 % CLD patients were screened. The HBV vaccination completion rate was 26% in 2005 compared with 36% in 2008. Although there was a lower percentage of screening in 2008, the overall number of patients tripled between 2005 and 2008. There was a significant increase in the total number of patients screened and vaccinated in 2008. Some physicians may have vaccinated their patients without checking for immunity. In January 2008, we implemented pre-printed order sets with checkboxes to help remind providers to order labs to screen for immunity against HAV and HBV and to order vaccinations for those who lacked immunity. The use of these sets may have aided in the increase of vaccination completion rates.

Entities:  

Keywords:  chronic liver disease; hepatitis A virus (HAV); hepatitis B virus (HBV); vaccination

Mesh:

Substances:

Year:  2016        PMID: 26836326      PMCID: PMC4962721          DOI: 10.1080/21645515.2015.1068484

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  13 in total

1.  Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine?

Authors:  G A Smallwood; C T Coloura; E Martinez; A C Stieber; T G Heffron
Journal:  Transplant Proc       Date:  2002-12       Impact factor: 1.066

2.  A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents.

Authors:  Eric E Mast; Harold S Margolis; Anthony E Fiore; Edward W Brink; Susan T Goldstein; Susan A Wang; Linda A Moyer; Beth P Bell; Miriam J Alter
Journal:  MMWR Recomm Rep       Date:  2005-12-23

3.  Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients.

Authors:  M R Arguedas; A Johnson; M A Eloubeidi; M B Fallon
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

4.  Deaths: final data for 2009.

Authors:  Kenneth D Kochanek; Jiaquan Xu; Sherry L Murphy; Arialdi M Miniño; Hsiang-Ching Kung
Journal:  Natl Vital Stat Rep       Date:  2011-12-29

5.  Seroepidemiology of hepatitis A in patients with chronic liver disease.

Authors:  S Saab; C Lee; A Shpaner; A B Ibrahim
Journal:  J Viral Hepat       Date:  2005-01       Impact factor: 3.728

6.  Immunogenicity of hepatitis A vaccine in decompensated liver disease.

Authors:  J A Dumot; D S Barnes; Z Younossi; S M Gordon; R K Avery; R E Domen; J M Henderson; W D Carey
Journal:  Am J Gastroenterol       Date:  1999-06       Impact factor: 10.864

7.  Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Anthony E Fiore; Annemarie Wasley; Beth P Bell
Journal:  MMWR Recomm Rep       Date:  2006-05-19

8.  Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination.

Authors:  Michael Shim; Inessa Khaykis; James Park; Edmund J Bini
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

9.  Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis.

Authors:  Marten Duncan; William K Hirota; Amy Tsuchida
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

Review 10.  Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases?

Authors:  E B Keeffe
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

View more
  2 in total

1.  Hepatitis A, B, and A/B vaccination series completion among US adults: A claims-based analysis.

Authors:  Parinaz K Ghaswalla; Brandon J Patterson; Wendy Y Cheng; Emilie Duchesneau; Monica Macheca; Mei Sheng Duh
Journal:  Hum Vaccin Immunother       Date:  2018-07-12       Impact factor: 3.452

2.  Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation - A Simple Intervention Ensures High Adherence.

Authors:  Toni Herta; David Petroff; Cornelius Engelmann; Adam Herber; Niklas Aehling; Uwe Scheuermann; Michael Bartels; Daniel Seehofer; Thomas Berg; Johannes Wiegand
Journal:  Ann Transplant       Date:  2019-09-13       Impact factor: 1.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.